Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.3752W HIGH $66.98
Volume
1.92 M
Value Traded
140.09 M
Short % Float
11.42%
Days to Cover
5.7
-1.99%Week
-7.86%1 Month
-11.26%3 Month
+56.83%6 Month
-34.67%5 Year
+123.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.85 B
EPS (TTM)
-0.65
P/E Ratio
-
Ent. Value
10.49 B
Total Shares
155.12 M
Float Shares
111.00 M
Insiders
27.15%
Institutions
93.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BRKR Catalyst Timeline
Dated clinical, regulatory and corporate events for Bruker Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bruker Corporation
4Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2027Coverage
Past FDA Catalysts and PDUFA Decisions
How BRKR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Bruker Corporation is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BRKR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Munch MarkOfficer (EXEC VP&PRES BRUKER NANO INC.) | Option | 2,000 136,806 held | $22.19 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BRKR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.4 % (33.3 %) | 9.03 M | 150.00 K | 20% ( 25.00 K) |
BRKR Institutional Ownership Trends
BRKR Short Interest
Shares sold short, counted twice a month.
11.42%
Short % of Float
of tradable shares sold short
12.7M
Shares Sold Short
+2.2% vs prior count
5.7 High
Days to Cover
trading days of normal volume to buy every short share back
2.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BRKR ranks across every disease it competes in
Competitive Position is a premium feature
See how BRKR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBRKR News
BRKR▲ +5.7%on this news
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
Bruker Corporation will release its third quarter 2026 financial results on November 4, 2026, before market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. Investors can pre-register for the call to streamline their entry.
Read more →BRKR▼ -5.3%on this news
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
Bruker Corporation announced a significant advancement in proteomics with the discovery of 179,000 plasma proteoforms, detailed in a draft atlas at isoform resolution. Conducted by researchers at Charité, this study highlights the extensive molecular diversity in human plasma, which may redefine approaches to biomarker discovery and drug development. The innovative use of timsTOF mass spectrometry enables a deeper understanding of protein functions and disease mechanisms.
Read more →BRKRBruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Bruker Corporation has unveiled new timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026. These workflows aim to enhance protein-sequence coverage and facilitate targeted validation, mobility-resolved glycopeptide characterization, and structural proteomics. The introduction of multi-enzyme dia-PASEF is expected to provide additional peptide information, advancing research in drug discovery and disease biology.
Read more →BRKRBruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
Bruker Corporation has secured a multi-system order from UC Berkeley for high-field NMR instrumentation. This investment aims to enhance the university's research capabilities by providing access to next-generation NMR technologies, including 800 MHz-class instrumentation. The upgrade will benefit various research areas such as chemistry, materials science, and structural biology.
Read more →BRKRBruker Corporation to Present at Upcoming Investor Conferences
Bruker Corporation has announced that its senior leadership will present at several upcoming investor conferences. These include the Wells Fargo 21st Annual Healthcare Conference in Boston, the Morgan Stanley 24th Annual Global Healthcare Conference in New York City, and the Bank of America Global Healthcare Conference in London. The presentations are scheduled for September 2026.
Read more →BRKRBruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
Bruker Corporation has announced an expanded strategic collaboration with Atinary Technologies, focusing on Self-Driving Labs® technologies and AI-driven research and development. This partnership aims to enhance applications in various sectors, including pharmaceuticals and materials. Additionally, Bruker has made a minority investment in Atinary, although financial details remain undisclosed.
Read more →BRKR▲ +5.4%on this newsshared move
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
Bruker Corporation has announced a majority investment in MIMETAS B.V., a company specializing in organ-on-a-chip platforms and advanced human tissue models. This investment aims to enhance Bruker's post-genomic solutions for disease biology and drug development. The collaboration will focus on Microphysiological Systems, which are crucial for advancing drug discovery methodologies.
Read more →BRKR▼ -21.8%on this news
Bruker Reports Second Quarter 2026 Financial Results
Bruker Corporation reported its financial results for Q2 2026, highlighting a return to organic revenue growth. The Scientific Instruments segment experienced a 10% increase in organic bookings year-over-year. The company's focus on cost management led to significant margin expansion and growth in non-GAAP earnings per share.
Read more →BRKRBruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
Bruker Corporation has announced that it will release its second quarter 2026 financial results on August 4, 2026, before the market opens. Following the release, the company will host a conference call and webcast at 9:00 a.m. EDT to discuss the results and current business trends. Investors can access the webcast through the company's investor relations website.
Read more →BRKRBruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
Bruker Corporation has acquired the DISQVER® clinical metagenomics platform from Noscendo GmbH. This acquisition enhances Bruker's capabilities in infection detection through metagenomic next-generation sequencing (mNGS). The DISQVER® platform enables the analysis of microbes directly from blood samples without prior cultivation, utilizing advanced bioinformatics.
Read more →BRKRBruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
Bruker has introduced the timsMRMS mass spectrometry platform aimed at addressing unique ultra-complex mixture applications in the energy sector. This launch highlights Bruker's commitment to advancing analytical technology. The new platform is expected to enhance the capabilities of researchers and professionals working with complex mixtures in energy-related fields.
Read more →BRKRBruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Bruker has announced significant advancements in 4D proteomics, focusing on intact and top-down functional proteoform analysis. These innovations are designed to enhance the understanding of disease biology. The company's developments in hybrid qual/quant 4D metabolomics further support this goal, promising deeper insights for researchers.
Read more →BRKR▲ +11.3%on this news
Bruker Reports First Quarter 2026 Financial Results
Bruker Corporation reported its Q1 2026 financial results, revealing revenues of $823.4 million, a 2.7% increase from the previous year. Despite facing challenges such as decreased organic revenue and tariff pressures, the company noted strong bookings in its BSI segment and reaffirmed its FY26 guidance. The introduction of new products at recent conferences has further solidified its market position.
Read more →BRKRBruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation has announced that it will release its first quarter 2026 financial results on May 6, 2026, before market opening. A conference call and webcast will follow at 8:00 a.m. Eastern Time to discuss these results and business trends. Investors can pre-register for the call to streamline their participation.
Read more →BRKRBruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
Bruker has announced significant enhancements to its microbial identification and outbreak management solutions at ESCMID Global 2026. Key updates include the introduction of the MBT Easy T® Kit for streamlined workflows, expansion of reference libraries, and the launch of a cloud-based MALDI identification solution. These innovations aim to improve laboratory efficiency and address evolving infectious disease challenges.
Read more →BRKRBruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Bruker has announced the launch of its MyGenius PRO® system, a high-throughput sample-to-answer molecular diagnostics system, at the ESCMID 2026 event. This system aims to enhance diagnostic capabilities in molecular testing. Further details on its features and applications were not provided in the article.
Read more →BRKRBruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Bruker Spatial Biology presented high fidelity spatial data and integrated multi-platform workflows at AACR 2026. The focus was on delivering unprecedented multiomic insights. However, specific details about the findings or technologies were not provided in the article.
Read more →BRKRBruker Unveils New NMR Products and Workflow Solutions at ENC 2026
Bruker has introduced new NMR products and workflow solutions at the ENC 2026 event. The announcement highlights the company's commitment to advancing nuclear magnetic resonance technology. Details on the specific products and their applications were not disclosed in the article.
Read more →BRKRBruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
Bruker has made an investment in photothermal AFM-IR technology aimed at enhancing semiconductor research. This move is expected to bolster their capabilities in this field. Further details on the specific applications or expected outcomes of this investment were not provided in the article.
Read more →BRKRBruker Announces Appointment of Thierry Bernard to its Board of Directors
Bruker Corporation has appointed Thierry L. Bernard to its Board of Directors, effective immediately. Bernard, currently the CEO of QIAGEN, has a strong background in the life-science tools and diagnostics industry. His experience is expected to contribute to Bruker's growth in life-science research and diagnostics. Bernard expressed enthusiasm about joining the board and supporting Bruker's mission.
Read more →About Bruker Corporation
Headquarters40 MANNING RD, BILLERICA, MA, 01821
BIOPHARMAWATCH ELITE PLUS
Trade the next BRKR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime